These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38342850)

  • 1. Effect of different starting doses of FSH on laboratory and clinical outcomes in patients with moderate AMH level.
    Liu M; Wang C; He L; Pan X; Wu C; Pu X; Pan X
    Hormones (Athens); 2024 Jun; 23(2):331-338. PubMed ID: 38342850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.
    Andersen AN; Witjes H; Gordon K; Mannaerts B;
    Hum Reprod; 2011 Dec; 26(12):3413-23. PubMed ID: 21954280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of anti-Mullerian hormone for pregnancy outcomes following assisted reproductive techniques (ART) in Southwest China.
    Liu L; Sun XY; Yang H; Feng XJ; Lan YZ
    Reprod Health; 2022 Dec; 19(1):224. PubMed ID: 36514055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study.
    Papaleo E; Zaffagnini S; Munaretto M; Vanni VS; Rebonato G; Grisendi V; Di Paola R; La Marca A
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():94-99. PubMed ID: 27835829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
    Sadruddin S; Barnett B; Ku L; Havemann D; Mucowski S; Herrington R; Burggren W
    PLoS One; 2020; 15(10):e0239779. PubMed ID: 33044971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles.
    Dai X; Wang Y; Yang H; Gao T; Yu C; Cao F; Xia X; Wu J; Zhou X; Chen L
    Sci Rep; 2020 Nov; 10(1):19750. PubMed ID: 33184364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Anti-Müllerian Hormone and
    Sun XY; Lan YZ; Liu S; Long XP; Mao XG; Liu L
    Front Endocrinol (Lausanne); 2020; 11():595448. PubMed ID: 33343511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
    van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM;
    Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are the likely IVF/ICSI outcomes if there is a discrepancy between serum AMH and FSH levels? A multicenter retrospective study.
    Daney de Marcillac F; Pinton A; Guillaume A; Sagot P; Pirrello O; Rongieres C
    J Gynecol Obstet Hum Reprod; 2017 Oct; 46(8):629-635. PubMed ID: 28843783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High anti-Müllerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment.
    Sun TC; Zhou SJ; Song LL; Li JH; Chen X; Tian L
    JBRA Assist Reprod; 2021 Apr; 25(2):266-271. PubMed ID: 33710839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve.
    Di Paola R; Garzon S; Giuliani S; Laganà AS; Noventa M; Parissone F; Zorzi C; Raffaelli R; Ghezzi F; Franchi M; Zaffagnini S
    Arch Gynecol Obstet; 2018 Nov; 298(5):1029-1035. PubMed ID: 30242498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.
    Sopa N; Larsen EC; Westring Hvidman H; Andersen AN
    Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():42-47. PubMed ID: 31009858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.